Reddy’s calls on FDA to inspect at Duvvada
Dr Reddy’s Laboratories has requested the US Food and Drug Administration (FDA) schedule an inspection of the firm’s oncology formulation manufacturing facility in Duvvada, Andhra Pradesh, India, as part of the firm’s ongoing attempts to resolve agency concerns at the firm’s two warning letter-stricken plants.
You may also be interested in...
Dr Reddy’s has been given the all-clear for its Indian formulations manufacturing facility in Duvvada, Visakhapatnam, after the FDA issued an EIR closing out an inspection at the plant that has suffered longstanding quality issues.
“Innovating cancer care for patients is a winning strategy,” Coherus said as it delivered on the first US biosimilar version of Amgen’s dominant pegfilgrastim formulation, using an on-body device to deliver the medication, months after a protracted FDA approval.
Hikma welcomed a strong and profitable 2023, driven by the nourishing effects of its authorized generic Xyrem product, which will fall back this year as the rate of royalties owed to the brand’s innovator climbs. But the company is optimistic it can continue growth in 2024, including through its $1.2bn Injectables division, which rushed in to fill supply gaps last year.